KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Other Operating Expenses (2016 - 2017)

Historic Other Operating Expenses for Pfizer (PFE) over the last 8 years, with Q4 2017 value amounting to -$7.1 billion.

  • Pfizer's Other Operating Expenses rose 1089.99% to -$7.1 billion in Q4 2017 from the same period last year, while for Sep 2018 it was -$7.1 billion, marking a year-over-year increase of 7071.53%. This contributed to the annual value of -$23.3 billion for FY2017, which is 531.02% up from last year.
  • According to the latest figures from Q4 2017, Pfizer's Other Operating Expenses is -$7.1 billion, which was up 1089.99% from -$5.6 billion recorded in Q4 2017.
  • Pfizer's 5-year Other Operating Expenses high stood at $1.1 billion for Q2 2013, and its period low was -$7.9 billion during Q4 2016.
  • Its 5-year average for Other Operating Expenses is -$4.0 billion, with a median of -$5.3 billion in 2015.
  • In the last 5 years, Pfizer's Other Operating Expenses surged by 25552.33% in 2013 and then tumbled by 1006037.74% in 2015.
  • Pfizer's Other Operating Expenses (Quarter) stood at $18.0 million in 2013, then skyrocketed by 194.44% to $53.0 million in 2014, then plummeted by 14730.19% to -$7.8 billion in 2015, then fell by 2.46% to -$7.9 billion in 2016, then rose by 10.9% to -$7.1 billion in 2017.
  • Its last three reported values are -$7.1 billion in Q4 2017, -$5.6 billion for Q4 2017, and -$5.4 billion during Q3 2017.